Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc

Bullboard Posts

Comment by pool1212on Feb 04, 2012 8:10am

297 Views

Post# 19489802

RE: what's going on today?

not sure but the volume and price increase might be a result of the Glaucoma: 360 - New Horizons forum being held Feb 2-4 in San Fran where ICO is, but do not know the extent of their attendance.

not anticipating any royalty payments this soon but may have anoher distribution agreement in the works

annual financials also coming sometime over the next few months, when made public (Dec 31 is the end of their financial year)

Bullboard Posts

Investors eye Australian gold mining projects amid promising developments